Prime Medicine (PRME)ARK Investment Management reduced its stake -109K shares

5.37M

Shares reported · -109K vs prior quarter

0.12%

Disclosed portfolio weight

$18.6M

Reported value

Holdings as of

Dec 31, 2025

Filed

Feb 11, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

What came next

1. Mar 3, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
2. Apr 7, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On April 7, 2026, the Board of Directors (the “Board”) of Prime Medicine, Inc. (the “Company”) appointed Svetlana Makhni as the Chief Financial Officer and the principal financial officer of the Company effective as of April 16, 2026.”
3. May 7, 2026Company filing · Form 8-K · ResultsReported its results

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Prime Medicine

For Prime Medicine, OQRO holds 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its PRME page.

How this filing works

• SEC Form 13F

Other disclosures at Prime Medicine

• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRMay 12, 2026
• SEC Form 13F-HRNov 12, 2025
• SEC Form 4Aug 5, 2025
• SEC Form 4Aug 1, 2025
• SEC Form 4Aug 1, 2025

Everything OQRO holds on this company is on its PRME page.